N/A N=50 Exercise and Markers of Medial Temporal Health in Youth At-risk for Psychosis
Attenuated Psychosis Syndrome
Primary: Brain Volume — 19.8; 54.8; -0.489; -6.28 Change in mm cubed (baseline -followup)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=76 ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors
Essential Tremor
Primary: Tremor Motor Score - Clinical Rating Scale for Tremor (CRST Part A (Upper Extremity) + Part B) Percent Change From Baseline — 46.9; -0.1 Percent Change from Baseline…
N/A N=58 Cost-minimization Analysis of Gastric Cancer Treatments in Hong Kong
Gastric Cancer
Primary: Expected and Unexpected Provider Costs — 2264.1; 522; 1135.7; 846 HK$
N/A N=24 Novel by Upper Airway Respiratory Muscle Training to Treat OSA in Chronic SCI
OSA · SCI/D · Upper Airway Exercise
Primary: Feasibility-Number of Participants Who Complete the Three-month Protocol — 8; 10 Participants
Phase 3 N=521 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
Breast Cancer
Primary: Pathological Complete Response (pCR) Rate — 24.5; 13.8 Percentage of participants — p=0.0021
N/A N=70 Safety and Effectiveness of Nintedanib in Korean Patients
Idiopathic Pulmonary Fibrosis
Primary: Number of Patients With Adverse Events Who Took at Least One Dose of Ofev — 36 Participants
Phase 1 N=40 A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
Healthy
Primary: Paired Associate Learning (PAL) Total Errors Adjusted (PALTEA28) on Ketamine — 24.169; 23.829; 28.170; 22.911 Errors — p=0.9296
Phase 4 N=19 Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
Cardiac Allograft Vasculopathy
Primary: Macitentan: Nitroglycerin (NTG) Luminal Dilation Ratio as Proportion of Vasomotor Tone Attributable to Endothelin-1 (ET-1) — 0.33; 0.30 ratio
N/A N=64 Development of a Resiliency Training Program for Parents of Children With Autism Spectrum Disorder
Stress
Primary: Distress — -1.35; -.36 score on a scale — p=.23
Phase 1 N=30 A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
Covid-19 · Coronavirus Disease 2019
Primary: AUC of Bempegaldesleukin [Pharmacokinetic Parameter]. — 153.2; 997.4; 2704.7 hr*ng/ml
N/A N=300 Post-Embolic Rhythm Detection With Implantable Versus External Monitoring
Stroke · Atrial Fibrillation · Arrhythmias, Cardiac
Primary: Definite AF or Highly Probable AF — 23; 7 Participants — p=0.003
N/A N=34 Study of Cellutome System for Treatment of Individual Lesions in EB Pts
Epidermolysis Bullosa
Primary: Percentage of Grafts Successfully Treated — 78 Percentage of grafts
Phase 3 N=35 Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis
Primary Hemophagocytic Lymphohistiocytosis
Primary: Overall Response at Week 8 or End of Treatment (if Earlier) — 62.9; 50.0; 73.7 Percentage of participants — p=0.0053
Phase 3 N=579 A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast Cancer
Primary: Cohort A: Progression-Free Survival (PFS) — 6.1; 7.4 months — p=0.9237
Phase 2 N=20 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Graft Failure — 0; 1 Participants